• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Be Biopharma

Be Biopharma

Advancing our science with bold humanity

  • Investors & Media
    • News Releases
    • Publications & Presentations
  • Careers
  • Contact Us
  • Search
  • Our Company
    • About Be Bio
    • Life at Be Bio
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • About BCMs
    • Our Platform
    • Publications & Presentations
  • Patients & Caregivers
Home/Our Science/Publications & Presentations

Publications & Presentations

Molecular Therapy|February 6, 2025

In vivo tracking of ex-vivo-generated 89Zr-oxine-labeled plasma cells by PET in a non-human primate model

Read More about In vivo tracking of ex-vivo-generated 89Zr-oxine-labeled plasma cells by PET in a non-human primate model

ASH 2024|December 8, 2024

BeCoMe9-A Phase 1/2 Dose Escalation and Expansion Study of BE-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B

Read More about BeCoMe9-A Phase 1/2 Dose Escalation and Expansion Study of BE-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B

ASH 2024|December 7, 2024

A versatile B cell engineering platform enables development of B Cell Medicines for sustained delivery of therapeutic biologics

Read More about A versatile B cell engineering platform enables development of B Cell Medicines for sustained delivery of therapeutic biologics

Molecular Therapy|July 2, 2024

Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing

Read More about Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing

Nature Biotechnology|June 17, 2024

B cells as drug factories

Read More about B cells as drug factories

Keystone Symposia on Emerging Cellular Therapies|January 24, 2024

Development of an Ex Vivo Precision Gene Engineered B Cell Medicine Platform that Produces Active and Sustained Levels of Therapeutic Proteins with Broad Utility

Read More about Development of an Ex Vivo Precision Gene Engineered B Cell Medicine Platform that Produces Active and Sustained Levels of Therapeutic Proteins with Broad Utility

ASH 2023|December 10, 2023

Development of an Ex Vivo Precision Gene Engineered B Cell Medicine that Produces Active and Sustained Levels of FIX for the Treatment of Hemophilia B

Read More about Development of an Ex Vivo Precision Gene Engineered B Cell Medicine that Produces Active and Sustained Levels of FIX for the Treatment of Hemophilia B

Society for Immunotherapy of Cancer (SITC)|November 4, 2023

“Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics”

Read More about “Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics”

ASGCT 2023|May 19, 2023

Rhesus Antibody Secreting Cells Differentiated ex vivo from B Cells Engraft Without Preconditioning in an Autologous Host and Represent a Novel Modality for Cell and Gene Therapy

Read More about Rhesus Antibody Secreting Cells Differentiated ex vivo from B Cells Engraft Without Preconditioning in an Autologous Host and Represent a Novel Modality for Cell and Gene Therapy

ASGCT 2023|May 18, 2023

CRISPR Engineering Primary Human B Cells for Sustained Secretion of Therapeutic Biologics

Read More about CRISPR Engineering Primary Human B Cells for Sustained Secretion of Therapeutic Biologics

ASGCT 2023|May 16, 2023

Development of an ex vivo Gene Engineered B Cell Medicine Platform with Precision, Modularity, and Broad Therapeutic Utility

Read More about Development of an ex vivo Gene Engineered B Cell Medicine Platform with Precision, Modularity, and Broad Therapeutic Utility

Nature Communications|October 16, 2022

Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo

Read More about Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo

PEGS Boston Summit|May 5, 2022

Rick Morgan, Be Bio CSO, PEGS Boston Summit: Engineered B Cells as a Novel Off-the-Shelf Oncology Therapy

Read More about Rick Morgan, Be Bio CSO, PEGS Boston Summit: Engineered B Cells as a Novel Off-the-Shelf Oncology Therapy

Nature Reviews Immunology|October 6, 2020

Transcriptional regulation of memory B cell differentiation

Read More about Transcriptional regulation of memory B cell differentiation

Frontiers in Immunology|September 11, 2019

Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells

Read More about Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells

Molecular Therapy|November 21, 2017

Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells

Read More about Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells

Trends in Cancer|December 1, 2016

B lymphocytes and cancer: a love-hate relationship

Read More about B lymphocytes and cancer: a love-hate relationship

Learn more about what it’s like to be part of the team powering this platform.

Life at Be Bio

Footer

Be Biopharma
LinkedIn X

info@be.bio

Contact Us

Careers

  • Our Company
    • About Be Bio
    • Life at Be Bio
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • About BCMs
    • Our Platform
    • Publications & Presentations
  • Patients & Caregivers
  • Investors & Media
    • News Releases
    • Publications & Presentations

©2023, Be Biopharma

Privacy Policy

logo
  • Our Company
    • About Be Bio
    • Life at Be Bio
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • About BCMs
    • Our Platform
    • Publications & Presentations
  • Patients & Caregivers
  • Investors & Media
    • News Releases
    • Publications & Presentations
  • Careers
  • Contact Us